What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks

被引:33
作者
Zhang, Mengmeng [1 ]
Bao, Yun [5 ]
Lang, Yitian [6 ]
Fu, Shihui [7 ]
Kimber, Melissa [1 ,2 ]
Levine, Mitchell [1 ,3 ]
Xie, Feng [1 ,4 ]
机构
[1] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] McMaster Univ, Offord Ctr Child Studies, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada
[3] McMaster Univ, Dept Med, Div Clin Pharmacol & Toxicol, Hamilton, ON, Canada
[4] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[5] Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Peoples R China
[6] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Pharm, Huangpu Branch,Sch Med, Shanghai, Peoples R China
[7] China Pharmaceut Univ, Sch Int Pharmaceut Business, Nanjing, Peoples R China
关键词
healthcare decision making; health technology assessment; value assessment frameworks; CRITERIA DECISION-ANALYSIS; ECONOMICS APPROACH; COVERAGE DECISIONS; PUBLIC-HEALTH; PRIORITIZATION; DRUGS; EXTRA; MCDA; RECOMMENDATIONS; INTERVENTIONS;
D O I
10.1016/j.jval.2021.07.005
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: This study aimed to investigate how value is defined and measured in existing value assessment frameworks (VAFs) in healthcare. Methods: We searched PubMed, Embase, the Cochrane Library, and Centre for Reviews and Dissemination from 2008 to 2019. We also performed backward citation chaining of included studies and previously published systematic reviews. Studies reporting the development of a VAF in healthcare were included. For each included framework, we extracted and compared the context, target users, intended use, methods used to identify value attributes, description of the attributes, and attribute scoring approaches. Results: Of the 8151 articles screened, 57 VAFs were included. The value attributes included in 55 VAFs were grouped into 9 categories: health benefits (n = 53, 96%), affordability (n = 45, 82%), societal impact (n = 42, 76%), burden of disease (n = 36, 65%), quality of evidence (n = 32, 58%), cost-effectiveness (n = 31, 56%), ethics and equity (n = 27, 49%), unmet needs (n = 21, 38%), and innovation (n = 15, 27%). The remaining 2 VAFs used broad attributes or user-defined attributes. Literature review was the main approach to identify value attributes in 36 VAFs. Patient or public was engaged through the development of only 11 VAFs. Weighting has been used to score 29 VAFs, of which 19 used the methods of multicriteria decision analysis. Conclusions: There are substantial variations in defining and measuring value. A noticeable weakness of existing VAFs is that patient or public engagement was generally very limited or missing in framework development process. Existing VAFs tend to aggregate multiple value attributes into a single index for decision making.
引用
收藏
页码:302 / 317
页数:16
相关论文
共 104 条
[1]   GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction [J].
Alonso-Coello, Pablo ;
Schunemann, Holger J. ;
Moberg, Jenny ;
Brignardello-Petersen, Romina ;
Akl, Elie A. ;
Davoli, Marina ;
Treweek, Shaun ;
Mustafa, Reem A. ;
Rada, Gabriel ;
Rosenbaum, Sarah ;
Morelli, Angela ;
Guyatt, Gordon H. ;
Oxman, Andrew D. .
BMJ-BRITISH MEDICAL JOURNAL, 2016, 353
[2]   Prioritisation of specialist health care services; not NICE, not easy but it can be done [J].
Anderson, Pippa ;
Webb, Philip ;
Groves, Sam .
HEALTH POLICY, 2017, 121 (09) :978-985
[3]   ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations [J].
Angelis, Aris ;
Kanavos, Panos ;
Phillips, Lawrence D. .
VALUE IN HEALTH, 2020, 23 (08) :1040-1048
[4]   Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework [J].
Angelis, Aris ;
Kanavos, Panos .
SOCIAL SCIENCE & MEDICINE, 2017, 188 :137-156
[5]  
[Anonymous], 2012, Healthc Manage Forum
[6]  
[Anonymous], NCCN CLIN PRACTICE G
[7]   Distributional Cost-Effectiveness Analysis: A Tutorial [J].
Asaria, Miqdad ;
Griffin, Susan ;
Cookson, Richard .
MEDICAL DECISION MAKING, 2016, 36 (01) :8-19
[8]   Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology [J].
Badia, Xavier ;
Aguaron, Alfonso ;
Fernandez, Ana ;
Gimon, Antonia ;
Nafria, Begona ;
Gaspar, Bernard ;
Guarga, Laura ;
Galvez, Maria ;
Fuentes, Marta ;
Paco, Noelia ;
Saldana, Roberto .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2019, 35 (01) :56-63
[9]   MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING [J].
Banos Roldan, Ursula ;
Badia, Xavier ;
Antonio Marcos-Rodriguez, Jose ;
de la Cruz-Merino, Luis ;
Gomez-Gonzalez, Jaime ;
Melcon-de Dios, Ana ;
Caraballo-Camacho, Maria de la O. ;
Cordero-Ramos, Jaime ;
Dolores Alvarado-Fernandez, Maria ;
Manuel Galiana-Auchel, Jose ;
Angel Calleja-Hernandez, Miguel .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2018, 34 (05) :519-526
[10]  
Berry F, U SYDNEY LIB CITATIO